Abstract
Zonisamide, originally known as an antiepileptic drug, has been approved in Japan as adjunctive therapy with levodopa for the treatment of Parkinson's disease (PD). Although zonisamide reduces neurotoxicity, the precise mechanism of this action is not known. Here, we show that zonisamide increases cell viability in SH-SY5Y cells via an anti-apoptotic effect and by upregulating levels of manganese superoxide dismutase (MnSOD). These results would give us novel evidences of PD treatment.
Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
-
Antioxidants / pharmacology*
-
Apoptosis / drug effects*
-
Caspases / metabolism
-
Cell Differentiation / drug effects
-
Dopamine / pharmacology
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Enzyme Inhibitors / pharmacology
-
Humans
-
In Situ Nick-End Labeling / methods
-
Isoxazoles / pharmacology*
-
Neuroblastoma / pathology
-
Neurotoxins / pharmacology
-
Staurosporine / pharmacology
-
Superoxide Dismutase / metabolism*
-
Up-Regulation / drug effects*
-
Zonisamide
Substances
-
Antioxidants
-
Enzyme Inhibitors
-
Isoxazoles
-
Neurotoxins
-
Zonisamide
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Superoxide Dismutase
-
Caspases
-
Staurosporine
-
Dopamine